Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE220067 | GEO | 2022/12/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

Project description:Inflammation has long been recognized to contribute to cancer development, particularly across the gastrointestinal tract. Patients with inflammatory bowel disease have an increased risk for bowel cancers, and it has been posited that a field of genetic changes may underlie this risk. Here, we define the clinical features, genomic landscape, and germline alterations in 174 patients with colitis-associated cancers and sequenced 29 synchronous or isolated dysplasia. TP53 alterations, an early and highly recurrent event in colitis-associated cancers, occur in half of dysplasia, largely as convergent evolution of independent events. Wnt pathway alterations are infrequent, and our data suggest transcriptional rewiring away from Wnt. Sequencing of multiple dysplasia/cancer lesions from mouse models and patients demonstrates rare shared alterations between lesions. These findings suggest neoplastic bowel lesions developing in a background of inflammation experience lineage plasticity away from Wnt activation early during tumorigenesis and largely occur as genetically independent events. Colitis-associated cancers (CACs) develop in patients with inflammatory bowel disease and have distinct genomic features compared to sporadic colorectal cancers. Here, the authors characterize the genomic alterations of CAC tumors and dysplasia, finding decreased Wnt signaling and a lack of shared early genetic steps.

| S-EPMC9825391 | biostudies-literature

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_Z]

2022-12-07 | GSE220066 | GEO

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_W]

2022-12-07 | GSE220063 | GEO

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_Q]

2022-12-07 | GSE220061 | GEO

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

Project description:Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

| PRJNA908740 | ENA

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_Z]

Project description:Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_Z]

| PRJNA908748 | ENA

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_W]

Project description:Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_W]

| PRJNA908745 | ENA

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_Q]

Project description:Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers [Proj_07182_Q]

| PRJNA908744 | ENA

Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis.

Project description:Inflammatory bowel disease (IBD) is a chronic disorder of the gastrointestinal tract that has limited treatment options. To gain insight into the pathogenesis of chronic colonic inflammation (colitis), we performed a multiomics analysis that integrated RNA microarray, total protein mass spectrometry (MS), and phosphoprotein MS measurements from a mouse model of the disease. Because we collected all three types of data from individual samples, we tracked information flow from RNA to protein to phosphoprotein and identified signaling molecules that were coordinately or discordantly regulated and pathways that had complex regulation in vivo. For example, the genes encoding acute-phase proteins were expressed in the liver, but the proteins were detected by MS in the colon during inflammation. We also ascertained the types of data that best described particular facets of chronic inflammation. Using gene set enrichment analysis and trans-omics coexpression network analysis, we found that each data set provided a distinct viewpoint on the molecular pathogenesis of colitis. Combining human transcriptomic data with the mouse multiomics data implicated increased p21-activated kinase (Pak) signaling as a driver of colitis. Chemical inhibition of Pak1 and Pak2 with FRAX597 suppressed active colitis in mice. These studies provide translational insights into the mechanisms contributing to colitis and identify Pak as a potential therapeutic target in IBD.

| S-EPMC6719711 | biostudies-literature

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

Project description:DNA focused panel sequencing has been rapidly adopted to assess therapeutic targets in advanced/refractory cancer. Integrated Genomic Profiling (IGP) utilising DNA/RNA with tumour/normal comparisons in a Clinical Laboratory Improvement Amendments (CLIA) compliant setting enables a single assay to provide: therapeutic target prioritisation, novel target discovery/application and comprehensive germline assessment. A prospective study in 35 advanced/refractory cancer patients was conducted using CLIA-compliant IGP. Feasibility was assessed by estimating time to results (TTR), prioritising/assigning putative therapeutic targets, assessing drug access, ascertaining germline alterations, and assessing patient preferences/perspectives on data use/reporting. Therapeutic targets were identified using biointelligence/pathway analyses and interpreted by a Genomic Tumour Board. Seventy-five percent of cases harboured 1-3 therapeutically targetable mutations/case (median 79 mutations of potential functional significance/case). Median time to CLIA-validated results was 116 days with CLIA-validation of targets achieved in 21/22 patients. IGP directed treatment was instituted in 13 patients utilising on/off label FDA approved drugs (n = 9), clinical trials (n = 3) and single patient IND (n = 1). Preliminary clinical efficacy was noted in five patients (two partial response, three stable disease). Although barriers to broader application exist, including the need for wider availability of therapies, IGP in a CLIA-framework is feasible and valuable in selection/prioritisation of anti-cancer therapeutic targets.

| S-EPMC5431338 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data